The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Harm potential of magic mushroom use: A review
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“However, a study by Griffiths et al. (2006) reported that 22% (8 of 36) of the volunteers treated with up to 30 mg psilocybin per 70 kg experienced a period of notable anxiety/dysphoria during the session, some times including transient ideas of reference or paranoia, despite several prior meetings…”
BackgroundAnthony, J. C., Warner, L. A., & Kessler, R. C. (1994) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.2.3.244 · Cited by 1,341
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1×
“Similar low harm ratings for magic mushrooms were reported by two expert groups in the UK (Nutt et al., 2010, 2007; van Amsterdam et al., 2010).”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“It should be noted that psilocybin (100– 250 lg/kg p.o.) affects the subjective perception of time, synchronization and tapping tempo, working memory and subjective changes in conscious state (Hasler et al., 2004), which largely impairs car driving and handling of machines (Wittmann et al., 2007).”
BackgroundStuderus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 1×
“A recent metaanalysis of 110 healthy subjects, treated 1–4 times under controlled conditions with 45–315 lg/kg body weight, reported no serious psychological adverse effects (Studerus et al., 2010).”
BackgroundHasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Ranking the Harm of Alcohol, Tobacco and Illicit Drugs for the Individual and the Population
van Amsterdam, J., Opperhuizen, A., Koeter, M., & van den Brink, W. (2010) · European Addiction Research · doi:10.1159/000317249 · Cited by 191
Self-citationCross tolerance between LSD and psilocybin
Isbell, H., Wolbach, A. B., Wikler, A., & Miner, E. J. (1961) · Psychopharmacologia · doi:10.1007/bf00407974 · Cited by 137 · cited 1×
“Tolerance to the psychedelic effects of psilocybin develops rapidly, but withdrawal symptoms and psychological dependency do not occur (Abramson and Rolo, 1965; Isbell et al., 1961) or are very rare compared to all other (illegal) drugs (Anthony et al., 1994; Stone et al., 2006; Stone et al., 2007).”
BackgroundCarter, O. L., Pettigrew, J. D., Hasler, F., Wallis, G. M., Liu, G. B., Hell, D., & Vollenweider, F. X. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300621 · Cited by 118
Do hallucinogens cause residual neuropsychological toxicity?
Halpern, J. H., & Pope, H. G. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00129-x · Cited by 82
Cited by
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 553
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Psychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
Dinis-Oliveira, R. J. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1278228 · Cited by 224
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“…have found that psychedelics and cannabinoids in particular exhibit relatively lower risk of harm to the user and society than other currently available drugs such as alcohol and tobacco (Carhart-Harris & Nutt, 2013; Fantegrossi et al., 2004; Nutt et al., 2010; Van Amsterdam et al., 2010, 2011).”
BackgroundInfluentialSmigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X. (2019) · Scientific Reports · doi:10.1038/s41598-019-50612-3 · Cited by 176
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Winkelman, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107120011 · Cited by 126
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Van Court, R. C., Wiseman, M. S., Meyer, K. W., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B. T. M., Garibay-Orijel, R., & Uehling, J. K. (2022) · Fungal Biology · doi:10.1016/j.funbio.2022.01.003 · Cited by 94
Psychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86
Nkadimeng, S. M., Steinmann, C. M., & Eloff, J. N. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s317182 · Cited by 83
Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.041 · Cited by 72
Zamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71
Psychedelic therapy: a roadmap for wider acceptance and utilization
Marks, M., & Cohen, I. G. (2021) · Nature Medicine · doi:10.1038/s41591-021-01530-3 · Cited by 59
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
Honyiglo, E., Franchi, A., Cartiser, N., Bottinelli, C., Advenier, A., Bévalot, F., & Fanton, L. (2019) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13982 · Cited by 35
Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness
Studerus, E. (2012) · University of Zurich · doi:10.5167/uzh-164092 · Cited by 6
Metadata
- Authors
- Amsterdam, J. V., Opperhuizen, A., & Brink, W. V. D.
- Venue
- Regulatory Toxicology and Pharmacology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 59
- Issue
- 3
- Pages
- 423-429
- ISSN
- 0273-2300 (ISSN-L)
- OpenAlex
- W2065164655
- Cited by
- 208
- References
- 10
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.